Home LiteratureArticle Details
PMID: 18094155 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.

Journal of virology ·Vol. 82 ·No. 5 ·2008-03-00 ·Pages 2367-75

Gray ES, Moore PL, Bibollet-Ruche F, Li H, Decker JM, Meyers T, Shaw GM, Morris L

Abstract

The broadly neutralizing monoclonal antibody (MAb) 4E10 recognizes a linear epitope in the C terminus of the membrane-proximal external region (MPER) of gp41. This epitope is particularly attractive for vaccine design because it is highly conserved among human immunodeficiency virus type 1 (HIV-1) strains and neutralization escape in vivo has not been observed. Multiple env genes were cloned from an HIV-1 subtype C virus isolated from a 7-year-old perinatally infected child who had anti-MPER neutralizing antibodies. One clone (TM20.13) was resistant to 4E10 neutralization as a result of an F673L substitution in the MPER. Frequency analysis showed that F673L was present in 33% of the viral variants and in all cases was linked to the presence of an intact 2F5 epitope. Two other envelope clones were sensitive to 4E10 neutralization, but TM20.5 was 10-fold less sensitive than TM20.6. Substitutions at positions 674 and 677 within the MPER rendered TM20.5 more sensitive to 4E10 but had no effect on TM20.6. Using chimeric and mutant constructs of these two variants, we further demonstrated that the lentivirus lytic peptide-2 domain in the cytoplasmic tail affected the accessibility of the 4E10 epitope, as well as virus infectivity. Collectively, these genetic changes in the face of a neutralizing antibody response to the MPER strongly suggested immune escape from antibody responses targeting this region.

MeSH Terms
Amino Acid Sequence Antibodies, Monoclonal/immunology Base Sequence Cell Line DNA Primers Drug Resistance, Viral HIV Envelope Protein gp41/chemistry,genetics HIV Infections/virology HIV-1/drug effects,genetics,immunology,pathogenicity Humans Molecular Sequence Data Neutralization Tests Sequence Homology, Amino Acid Virulence
Chemicals
Antibodies, Monoclonal DNA Primers HIV Envelope Protein gp41
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Gray Elin S
National Institute for Communicable Diseases, Johannesburg, Private Bag X4, Sandringham 2131, Johannesburg, South Africa.
Moore Penny L
Bibollet-Ruche Frederic
Li Hui
Decker Julie M
Meyers Tammy
Shaw George M
Morris Lynn
References (37)
37 references, click to expand
  1. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.
    J Virol. 1998 Feb;72(2):986-93 PMID: 9444991
  2. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  3. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
    J Virol. 2001 Nov;75(22):10892-905 PMID: 11602729
  4. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity.
    J Virol. 1999 Mar;73(3):2469-80 PMID: 9971832
  5. Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression.
    J Virol. 2001 Jun;75(11):5263-76 PMID: 11333908
  6. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    J Virol. 2006 Mar;80(6):3030-41 PMID: 16501112
  7. Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.
    Virology. 2007 Oct 10;367(1):102-16 PMID: 17582453
  8. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.
    J Virol. 2007 Jun;81(12):6187-96 PMID: 17409164
  9. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    J Virol. 2000 Sep;74(18):8358-67 PMID: 10954535
  10. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
    Nat Med. 2005 Jun;11(6):615-22 PMID: 15880120
  11. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    J Virol. 2005 Jan;79(2):1252-61 PMID: 15613352
  12. Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.
    J Virol. 2005 Oct;79(19):12455-63 PMID: 16160173
  13. Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41.
    J Virol. 2005 Feb;79(4):2097-107 PMID: 15681412
  14. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.
    J Virol. 2002 Mar;76(6):2683-91 PMID: 11861835
  15. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65 PMID: 11788027
  16. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
    J Virol. 2007 Aug;81(16):8793-808 PMID: 17567707
  17. The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.
    J Virol. 2005 Jan;79(1):106-15 PMID: 15596806
  18. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    J Virol. 2005 Apr;79(8):4991-9 PMID: 15795284
  19. Rational site-directed mutations of the LLP-1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope incorporation.
    J Virol. 2003 Mar;77(6):3634-46 PMID: 12610139
  20. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.
    J Virol. 1996 Mar;70(3):1651-67 PMID: 8627686
  21. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.
    Biochemistry. 2003 Dec 9;42(48):14150-8 PMID: 14640682
  22. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    J Virol. 2004 Dec;78(23):13232-52 PMID: 15542675
  23. The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring.
    AIDS. 2005 Nov 4;19(16):1725-37 PMID: 16227780
  24. In vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide.
    AIDS Res Hum Retroviruses. 2005 Sep;21(9):776-83 PMID: 16218801
  25. Multiple domains of the SIV Env protein determine virus replication efficiency and neutralization sensitivity.
    Virology. 2005 Feb 5;332(1):89-101 PMID: 15661143
  26. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10.
    J Mol Biol. 2007 Feb 2;365(5):1533-44 PMID: 17125793
  27. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.
    AIDS. 2005 Nov 18;19(17):1957-66 PMID: 16260901
  28. Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail.
    J Virol. 2005 Oct;79(19):12231-41 PMID: 16160149
  29. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
    J Virol. 2007 Apr;81(8):4033-43 PMID: 17287272
  30. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    J Virol. 2004 Oct;78(19):10724-37 PMID: 15367639
  31. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein.
    J Virol. 1993 May;67(5):2747-55 PMID: 8474172
  32. Dynamics of HIV-1 recombination in its natural target cells.
    Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4204-9 PMID: 15010526
  33. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.
    Immunity. 2005 Feb;22(2):163-73 PMID: 15723805
  34. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions.
    J Virol. 2003 May;77(10):5678-84 PMID: 12719560
  35. Cytosolic domain of the human immunodeficiency virus envelope glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteins.
    J Biol Chem. 1993 Oct 25;268(30):22895-9 PMID: 8226798
  36. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.
    PLoS Med. 2006 Jul;3(7):e255 PMID: 16834457
  37. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression.
    AIDS Res Hum Retroviruses. 2006 May;22(5):458-65 PMID: 16706624
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
1098-5514
Published
2008-03-00
Epub
2007-00-19
Pages
2367-75
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC2258954
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com